PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
96.69%
Cash & equivalents growing 96.69% while AVXL's declined -6.07%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
96.69%
Below half of AVXL's -6.07%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
119.86%
Higher Other Current Assets Growth compared to AVXL's zero value, indicating worse performance.
94.31%
Below half of AVXL's -7.00%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-6.34%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.92%
Both AVXL and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
78.33%
Below half of AVXL's -7.00%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-11.61%
Less than half of AVXL's 30.66%. David Dodd sees a more disciplined AP approach or lower volume.
-42.55%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
11.61%
Higher Deferred Revenue (Current) Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-11.56%
Less than half of AVXL's 30.66%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.36%
Higher Total Non-Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-11.23%
Less than half of AVXL's 30.66%. David Dodd sees far fewer liability expansions relative to competitor.
36.01%
Above 1.5x AVXL's 2.74%. Michael Burry suspects heavy new equity expansion or dilution.
-2.61%
Below half AVXL's -6.89%. Michael Burry suspects major net losses or high dividends vs. competitor.
-6.95%
Higher AOCI Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
193.87%
Below half AVXL's -17.66%. Michael Burry sees potential underperformance in building shareholder capital.
78.33%
Below half AVXL's -7.00%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-9.95%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
-116.79%
Less than half of AVXL's 6.07%. David Dodd sees better deleveraging or stronger cash buildup than competitor.